GLP-1 Market
LLY $1283.66 ▲ +3.5% NVO $39.35 ▲ +2.4% PFE $30.11 ▲ +2.3% VKTX $26.71 ▲ +6.6% KLRA $12.89 ▲ +12.8% GPCR $22.88 ▲ +4.0% RHHBY $59.11 ▲ +3.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

SC0062 strength

SC0062 strength

Company
University Medical Center Groningen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 21, 2026

Find a Clinical Trial Near Me

See recruiting studies for SC0062 strength and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06819826

    A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

    Not yet reported Biocity Biopharmaceutics Co., Ltd. 360 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: IgA Nephropathy (IgAN)
    View official trial listing →
  • Not yet recruiting NCT NCT06072326

    dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

    Not yet reported University Medical Center Groningen 36 participants Est. completion 2030-01 5 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: SC0062 strength, SC0062 strength 10mg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.